Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137327 | 1.00 | SSTR4 (0.39) | SSTR4GPR119NR1H2NAMPTJAK3 | |
| SCHEMBL20585957 | 0.80 | HCAR2 (0.41) | KDM4E | |
| SCHEMBL20585956 | 0.80 | HCAR2 (0.41) | KDM4E | |
| SCHEMBL20585954 | 0.80 | HCAR2 (0.41) | KDM4E | |
| SCHEMBL31141603 | 0.80 | NR1H2 (0.40) | SSTR4GPR119NR1H2NAMPTJAK3 | |
| SCHEMBL12539635 | 0.80 | PDE4B (0.47) | GPR119USP30KDM4E | |
| SCHEMBL29918474 | 0.79 | GPR119 (0.50) | GPR119KDM4E | |
| SCHEMBL12539534 | 0.79 | JAK2 (0.48) | GPR119USP30KDM4E | |
| SCHEMBL21137324 | 0.74 | MGLL (0.50) | SSTR4GPR119NR1H2NAMPTJAK3 | |
| SCHEMBL29638842 | 0.74 | MGLL (0.50) | SSTR4GPR119NR1H2NAMPTJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638658-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-08 | — | — | EP | disclosed |
| CN-110944992-B | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SSTR4 391/4885GPR119 107/4885NR1H2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.